Preparation method of pangolin scale recombinant keratin keratin-alpha / beta
By expressing and purifying pangolin keratin-α/β on CHO cells, the problem of using medicinal ingredients in pangolin scales is solved, high-purity extraction and biomedical applications are achieved, and wound healing and tissue repair are promoted.
Patent Information
- Application Number
- CN202411444062.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-19
AI Technical Summary
There is currently a lack of research on keratin and wound healing in pangolin scales, and it is difficult for the prior art to effectively utilize the medicinal ingredients in pangolin scales for clinical treatment of skin trauma.
Pangolin scale recombinant keratin-α/β was expressed on CHO cells by lentiviral packaging method, and high-purity pangolin scale recombinant keratin-α/β was obtained by reactor amplification culture and nickel column affinity chromatography.
The stable expression and high purity extraction of pangolin scale recombinant keratin are achieved, providing an effective alternative to promote wound healing and tissue repair, with biocompatible and low cytotoxicity.
Smart Images

Figure CN118978582A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, in particular to a method for preparing pangolin scale recombinant keratin-α / β. Background Art
[0002] Skin trauma is a common clinical disease, which is mainly manifested by damage to skin tissue. Severe cases may cause systemic secondary infection or even death. Therefore, how to promote rapid wound healing and avoid secondary infection and complications is a hot topic of research at home and abroad. In recent years, many natural medicines have achieved good clinical effects in promoting the healing of skin wounds. And with the rapid development of molecular biology and the widespread application of new clinical technologies, domestic and foreign scholars are paying more and more attention to the repair mechanism of natural medicine topical treatment of skin wounds.
[0003] Skin wound repair is a very complex biological process. Chinese herbal medicines are widely used in clinical treatment due to their natural ingredients and few side effects, but they still need more objective, comprehensive and in-depth research. In recent years, keratin from animal hair or scales, as a natural biological material, has been widely used in the treatment of severe scalds, burns, hemorrhagic ulcers and diabetic foot due to its good hemostasis and wound healing properties. At present, there is no research on keratin in pangolin scales and wound healing. However, our previous research found that pangolin scale extracts have a good repair effect on scalds and wound surfaces.
[0004] Keratin has a high content in animal epithelial tissues and is mainly a structural protein derived from differentiated cells of the ectoderm. Depending on whether the keratin is fibrotic, keratin can be divided into soft keratin and hard keratin. The difference between these two types of keratin lies in the difference in the amount of sulfur amino acids. Soft keratin usually appears in the skin and some other cell tissues. Fibrotic hard keratin is widely present in the epidermis of humans and animals and the inner membrane of eggshells. The main components of hair, feathers, hooves, shells, claws, horns, scales, etc. are hard keratin.
[0005] Keratin has a unique α-helix and β-fold structure. The disulfide bonds within and between molecules make it more stable and hard. It also has good biocompatibility, cell affinity and biodegradability. Therefore, it has broad application prospects in biomedical polymer materials. It has been used in chrome-tanned leather fillers, animal feed, rubber latex, cosmetics and hair care products, wound dressings, membranes, hydrogels, and other biomaterials. It can also be used for wound treatment.
[0006] Keratin is widely used in tissue repair due to its ability to quickly stop bleeding, reduce inflammation and promote cell proliferation. Currently, scientists have used keratin from feathers to prepare a series of keratin-based hydrogels, and used rats as a treatment model to confirm its tissue repair ability, biocompatibility and low cytotoxicity.
[0007] Animal traditional Chinese medicine has a history of thousands of years of application in my country, among which animal scales or horns have been widely used from ancient times to the present due to their definite therapeutic effects. In order to better protect and utilize pangolin resources, it is necessary to explore its main medicinal ingredients and find effective substitutes for the treatment of clinical diseases. Summary of the invention
[0008] In order to solve the above technical problems, the present invention provides a method for preparing pangolin scale recombinant keratin-α / β.
[0009] To achieve the above object, the present invention is implemented according to the following technical solutions: A method for preparing pangolin scale recombinant keratin-α / β comprises the following steps: S1. The pangolin scale recombinant keratin-α / β was expressed in CHO cells by lentiviral packaging method; S2. Obtain high-purity pangolin scale recombinant keratin-α / β through reactor amplification culture and nickel column affinity chromatography.
[0010] Furthermore, the step S1 specifically includes: S11. Synthesize the keratin-α / β gene sequence containing FLAG tag; clone the keratin-α / β gene into the pLenti-CMV-P2A-Puro vector using ClonExpress II One Step Cloning Kit; take 50μL DH5α in the clean bench, add 10μL ligation product, mix by pipetting, and place on ice for half an hour; then place in a 42℃ water bath for 90S, and place on ice for 1 min; then add 900μL LB culture medium in the clean bench, place in a 37℃ shaker for 50min, and centrifuge at 5000rpm; aspirate the remaining 250μL supernatant and evenly spread it on the Amp-resistant LB plate, and culture at 37℃ for 18h; S12, take 10 mL of the bacterial solution in the LB plate and centrifuge at 5000 rpm at room temperature to collect the bacteria, and remove the supernatant; S13, add 3 mL of solution P1 containing RNase A to resuspend the bacterial pellet; S14, add 3 mL of solution P2, immediately and gently invert upside down 6-8 times, and leave at room temperature for 5 min; S15, add 3mL solution P4, immediately and gently turn upside down 6-8 times to mix thoroughly, then white flocculent precipitate will appear, then leave at room temperature for about 10 minutes, centrifuge at 12000rpm for 10 minutes, and collect the supernatant; S16, adding the collected supernatant to the filter column CS in batches, centrifuging at 12000 rpm for 2 min, and collecting the filtrate; S17, add 0.3 times the volume of isopropanol to the filtrate, mix by inversion, and transfer to adsorption column CP4; S18, centrifuge at room temperature at 12000 rpm for 1 min, discard the waste liquid in the collection tube, and put the adsorption column back into the collection tube; S19, add 500 µL of deproteinized solution PD to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, pour out the waste liquid in the collection tube, and place the adsorption column CP4 in the collection tube; S110, add 600 µL of rinsing solution PW to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, pour out the waste liquid in the collection tube, and place the adsorption column CP4 in the collection tube; S111, add 600 µL of rinse solution PW to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, and discard the waste liquid in the collection tube; S112, placing the adsorption column CP4 back into the collection tube, centrifuging at 12000 rpm for 2 min, and leaving it at room temperature for several minutes to dry the remaining rinse solution in the adsorption material; S113, place the adsorption column CP4 in a clean centrifuge tube, add 100 µL of elution buffer TB to the middle part of the adsorption membrane, place at room temperature for 2 minutes, centrifuge at 12000 rpm for 1 minute to obtain the pLenti-CMV-Ha6-P2A-Hb4-3xFLAG-EF1a-Puro plasmid solution, collect it in a centrifuge tube, and store it at -20°C; S114. Human embryonic kidney cells HEK293T were cultured in a DMEM complete medium supplemented with 10% fetal bovine serum in an incubator at a temperature of 37° C. and a CO2 concentration of 5%, so that they were in an adherent growth state with a density of 80% and an epithelial-like vigorous growth state; S115. Before virus packaging, discard the old culture medium, add new DMEM complete medium containing 10% FBS (purchased from Gibco), and continue culturing in the incubator for 5 h; S116. Use 5 µg of pLenti-CMV-Ha6-P2A-Hb4-3xFLAG-EF1a-Puro plasmid solution, 4 µg of lentiviral packaging plasmid psPAX, and 1.5 µg of lentiviral packaging plasmid pMD2.G, add reduced serum medium Opti-MEM to 250 µL to prepare a plasmid mixture; use 31.2 µL of polyetherimide PEI, add reduced serum medium Opti-MEM to 250 µL to prepare polyetherimide transfection reduced serum medium PEI-Opti-MEM; add polyetherimide transfection reduced serum medium PEI-Opti-MEM to the plasmid mixture, flick the tube wall to mix, and incubate at room temperature for 15 minutes; S117, adding the mixed solution of step S116 dropwise to the culture solution of step S115, shaking gently to mix well, and continuing to culture in an incubator at a temperature of 37° C. and a CO2 concentration of 5%; S118. After 18 h, the culture medium was aspirated and 5 mL of freshly prepared DMEM complete culture medium containing 10% FBS was added; S119. After 48 h, the culture supernatant was collected, centrifuged, filtered with a 0.45-µm filter membrane, and quickly frozen in liquid nitrogen to obtain the recombinant virus solution, which was stored at -80°C; S120, take out the frozen CHO-K1 cells from the liquid nitrogen tank, shake and thaw them quickly in a 37°C water bath, transfer the thawed CHO-K1 cells to a centrifuge tube containing 5 mL of DMEM complete medium, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add 4-6 mL of complete medium and blow evenly, inoculate in a T25 culture flask, and culture overnight in an incubator at 37°C and a CO2 concentration of 5%. Change the medium and check the cell density on the second day. When the cell density reaches 80%-90%, add 1 mL of trypsin for digestion for 1 minute to separate the CHO-K1 cells into single cells, and terminate digestion; centrifuge, discard the supernatant, add DMEM complete medium containing 50% F-12K medium and 10% FBS to resuspend the CHO-K1 cells, and count; S121. Add 500 µL of recombinant virus solution to the six-well plate, and then immediately add 1×10 5 CHO-K1 cells were shaken and cultured in an incubator for 48 h as the experimental group. At the same time, 1×10 5 The CHO-K1 cells were shaken and cultured in an incubator for 48 h as a control group. S122. After the cells of the experimental group and the control group were cultured for 48 h, the DMEM complete medium containing 8 μg / mL puromycin, F-12K medium and 10% FBS was replaced, and then replaced every 48 h; S123. After 5 days of screening, all CHO-K1 cells in the control group died. At this time, the CHO-K1 cells in the experimental group that were not dead were positive CHO-K1 cells.
[0011] Furthermore, the step S2 specifically includes: S21, expanding and culturing the obtained positive CHO-K1 cells with a complete DMEM medium containing F-12K and 10% FBS to obtain a pangolin scale recombinant keratin-α / β culture fluid; S22. Purify the pangolin scale recombinant keratin-α / β culture medium using a GST-tagged protein purification affinity preloaded column to obtain high-purity pangolin scale recombinant keratin-α / β.
[0012] Compared with the prior art, the present invention firstly utilizes lentivirus packaging and CHO cells to prepare a cell line that can stably express α / β keratin of pangolin scales, and then expands the culture and purifies it to obtain high-purity pangolin scale recombinant keratin-α / β. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is the plasmid map of the overexpression vector Lenti-CMV-Ha6-P2A-Hb4-3xFLAG-EF1a-Puro.
[0014] Figure 2 These are the positive cells in the experimental group transfected with CHO-K1 cells.
[0015] Figure 3 This is the protein electrophoresis diagram of the target protein band showing the expected results in WB of the CHO-K1 cell gene overexpression stable cell line. DETAILED DESCRIPTION
[0016] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not used to limit the invention.
[0017] The raw materials, reagents, kits, equipment, etc. used in the following examples are all purchased from the market unless otherwise specified; among them: CHO-K1 cells, purchased from ATCC); DMEM complete medium, purchased from Gibco; fetal bovine serum FBS, purchased from Shanghai Biotech; 0.25% Trypsin-EDTA digestion solution (0.25% Trypsin-EDTA), purchased from Gibco; GlutaMAX (100X), purchased from Gibco; NEAA (100X), purchased from Starfish Bio; reduced serum medium Opti-MEM, purchased from Gibco; Chloroquine diphosphate, purchased from Sigma-Aldrich; Puromycin Dihydrochloride, purchased from Biosharp; DL10000 Ladder, purchased from Shanghai Biotech; cell / tissue genomic DNA extraction kit, purchased from Novex; FastPure Plasmid Mini Kit plasmid extraction kit, purchased from Novex; Omega / Endo-freeplasmid Mini Kit II-fast endotoxin-free plasmid extraction kit was purchased from Omega; PCR product recovery kit was purchased from Novazonics; BCA kit was purchased from Yazyme.
[0018] S1. The pangolin scale recombinant keratin-α / β was expressed in CHO cells by lentiviral packaging method; S11. Obtain the keratin-α / β gene sequence from Genbank and entrust Sangon Biotech (Shanghai) Co., Ltd. to synthesize the keratin-α / β gene sequence containing the FLAG tag. The gene sequence is as follows: The keratin-α / β gene was cloned into the pLenti-CMV-P2A-Puro vector (purchased from Guangzhou Aidi Gene) using ClonExpress II One Step Cloning Kit. 50 μL of DH5α was taken in the clean bench, and 10 μL of the ligation product was added to mix by pipetting, and then placed in an ice bath for half an hour; then placed in a 42°C water bath for 90 seconds, and then placed in an ice bath for 1 minute; then 900 μL of LB culture medium was added to the clean bench, and placed in a 37°C shaker for 50 minutes, and then centrifuged at 5000 rpm. The remaining 250 μL of the supernatant was evenly coated on an Amp-resistant LB plate, and cultured at 37°C for 18 hours; S12, take 10 mL of the bacterial solution in the LB plate and centrifuge at 5000 rpm at room temperature to collect the bacteria, and remove the supernatant; S13, add 3 mL of solution P1 (containing RNaseA) (from Omega / Endo-free plasmid Mini KitII-fast endotoxin-free plasmid extraction kit) to resuspend the bacterial pellet; S14, add 3 mL of solution P2 (from Omega / Endo-free plasmid Mini Kit II-fast endotoxin-free plasmid extraction kit), immediately and gently invert upside down 6-8 times, and leave at room temperature for 5 min; S15, add 3 mL of solution P4 (from Omega / Endo-free plasmid Mini Kit II-fast), immediately and gently turn upside down 6-8 times to mix thoroughly, then white flocculent precipitate will appear, then place at room temperature for about 10 minutes, centrifuge at 12000 rpm for 10 minutes, and collect the supernatant; S16, adding the collected supernatant to the filter column CS in batches, centrifuging at 12000 rpm for 2 min, and collecting the filtrate; S17, add 0.3 times the volume of isopropanol to the filtrate, mix by inversion, and transfer to adsorption column CP4; S18, centrifuge at room temperature at 12000 rpm for 1 min, discard the waste liquid in the collection tube, and put the adsorption column back into the collection tube; S19, add 500 µL of deproteinized solution PD to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, pour out the waste liquid in the collection tube, and place the adsorption column CP4 in the collection tube; S110, add 600 µL of rinsing solution PW to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, pour out the waste liquid in the collection tube, and place the adsorption column CP4 in the collection tube; S111, add 600 µL of rinse solution PW to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, and discard the waste liquid in the collection tube; S112, placing the adsorption column CP4 back into the collection tube, centrifuging at 12000 rpm for 2 min, and leaving it at room temperature for several minutes to dry the remaining rinse solution in the adsorption material; S113. Place the adsorption column CP4 in a clean centrifuge tube, add 100 µL of elution buffer TB to the middle part of the adsorption membrane, place at room temperature for 2 minutes, centrifuge at 12000 rpm for 1 minute to obtain the pLenti-CMV-Ha6-P2A-Hb4-3xFLAG-EF1a-Puro plasmid solution, collect it in a centrifuge tube, store it at -20℃ or send it for sequencing identification. The plasmid map is as follows: Figure 1 As shown; the correct recombinant plasmid was identified for subsequent experiments; S114. Human embryonic kidney cells HEK293T (purchased from ATCC) were cultured in a DMEM complete medium supplemented with 10% fetal bovine serum in an incubator at 37°C and a CO2 concentration of 5%, so that they were in an adherent growth state with a density of 80% and an epithelial-like vigorous growth state; S115. Before virus packaging, discard the old culture medium, add new DMEM complete medium containing 10% FBS (purchased from Gibco), and continue culturing in the incubator for 5 h; S116. Use 5 µg of pLenti-CMV-Ha6-P2A-Hb4-3xFLAG-EF1a-Puro plasmid solution, 4 µg of lentiviral packaging plasmid psPAX, and 1.5 µg of lentiviral packaging plasmid pMD2.G, add reduced serum medium Opti-MEM to 250 µL to prepare a plasmid mixture; use 31.2 µL of polyetherimide PEI, add reduced serum medium Opti-MEM to 250 µL to prepare polyetherimide transfection reduced serum medium PEI-Opti-MEM; add polyetherimide transfection reduced serum medium PEI-Opti-MEM to the plasmid mixture, flick the tube wall to mix, and incubate at room temperature for 15 minutes; S117, adding the mixed solution of step S116 dropwise to the culture solution of step S115, shaking gently to mix well, and continuing to culture in an incubator at a temperature of 37° C. and a CO2 concentration of 5%; S118, 18 h later, the culture medium was aspirated and 5 mL of freshly prepared DMEM complete culture medium containing 10% FBS (purchased from Gibco) was added; S119. After 48 h, the culture supernatant was collected, centrifuged, filtered with a 0.45-µm filter membrane, and quickly frozen in liquid nitrogen to obtain the recombinant virus solution, which was stored at -80°C; S120, take out the frozen CHO-K1 cells from the liquid nitrogen tank, shake and thaw them quickly in a 37°C water bath, transfer the thawed CHO-K1 cells to a centrifuge tube containing 5 mL of DMEM complete medium, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add 4-6 mL of complete medium and blow evenly, inoculate in a T25 culture flask, and culture overnight in an incubator at 37°C and a CO2 concentration of 5%. Change the medium and check the cell density on the second day. When the cell density reaches 80%-90%, add 1 mL of trypsin for digestion for 1 minute to separate the CHO-K1 cells into single cells, and terminate digestion; centrifuge, discard the supernatant, add DMEM complete medium containing 50% F-12K medium and 10% FBS to resuspend the CHO-K1 cells, and count; S121. Add 500 µL of recombinant virus solution to the six-well plate, and then immediately add 1×10 5 CHO-K1 cells were shaken and cultured in an incubator for 48 h as the experimental group. At the same time, 1×10 5 The CHO-K1 cells were shaken and cultured in an incubator for 48 h as a control group. S122. After the cells of the experimental group and the control group were cultured for 48 h, the DMEM complete medium containing 8 μg / mL puromycin, F-12K medium and 10% FBS was replaced, and then replaced every 48 h; S123. After 5 days of screening, all CHO-K1 cells in the control group died. At this time, the CHO-K1 cells in the experimental group that did not die were positive CHO-K1 cells. The microscopic image of the positive cells is as follows: Figure 2 As shown; S2. Obtain high-purity pangolin scale recombinant keratin-α / β through reactor amplification culture and nickel column affinity chromatography; S21, expanding and culturing the obtained positive CHO-K1 cells with a complete medium containing F-12K medium and 10% FBS (purchased from Gibco), to obtain pangolin scale recombinant keratin-α / β culture fluid; S22. Purify the pangolin scale recombinant keratin-α / β culture medium using a GST-tagged protein purification affinity preloaded column to obtain high-purity pangolin scale recombinant keratin-α / β.
[0019] Western Blot Validation 1) Total protein of overexpressing polyclonal cells, monoclonal cells and wild-type cells was extracted using RIPA lysis buffer, and the protein concentration of the samples was determined by BCA method; 2) Protein loading amount: 20 μg; 3) Prepare 10% separation gel and 5% concentration gel, perform SDS-PAGE electrophoresis, and transfer to membrane; 4) Immunohistochemical hybridization: primary antibody Monoclonal ANTI-FLAG® M2Clone M2 1:1000, 3% skim milk powder solution; secondary antibody (goat anti-mouse) 1:10000, 5% skim milk powder solution; 5) ECL chemiluminescence color development.
[0020] The expected target protein bands were obtained in the CHO-K1 cell gene overexpression stable cell line WB. Figure 3 As shown, W10 is the protein group extracted from CHO-K1 control cells, and W11 is the protein group extracted from CHO-K1 cells after recombinant keratin-α / β. Figure 3 It can be seen that the overexpression polyclonal CHO-K1 cell line was successfully constructed and can produce pangolin scale recombinant keratin-α / β.
[0021] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.
Claims
1. A method for preparing pangolin scale recombinant keratin-α / β, It is characterized in that The following steps are involved: S1. The pangolin scale recombinant keratin-α / β was expressed in CHO cells by lentiviral packaging method; S2. Obtain high-purity pangolin scale recombinant keratin-α / β through reactor amplification culture and nickel column affinity chromatography.
2. The method for preparing pangolin scale recombinant keratin-α / β according to claim 1, It is characterized in that The step S1 specifically includes: S11. Synthesize the keratin-α / β gene sequence containing FLAG tag; clone the keratin-α / β gene into the pLenti-CMV-P2A-Puro vector using ClonExpressII One Step Cloning Kit; take 50μL DH5α in the clean bench, add 10μL ligation product, mix by pipetting, and place on ice for half an hour; then place in a 42℃ water bath for 90S, and place on ice for 1 min; then add 900μL LB culture medium in the clean bench, place in a 37℃ shaker for 50min, and centrifuge at 5000rpm; aspirate the remaining 250μL supernatant and evenly spread it on the Amp-resistant LB plate, and culture at 37℃ for 18h; S12, take 10 mL of the bacterial solution in the LB plate and centrifuge at 5000 rpm at room temperature to collect the bacteria, and remove the supernatant; S13, add 3 mL of solution P1 containing RNase A to resuspend the bacterial pellet; S14, add 3 mL of solution P2, immediately and gently invert upside down 6-8 times, and leave at room temperature for 5 min; S15, add 3mL solution P4, immediately and gently turn upside down 6-8 times to mix thoroughly, then white flocculent precipitate will appear, then leave at room temperature for about 10 minutes, centrifuge at 12000rpm for 10 minutes, and collect the supernatant; S16, adding the collected supernatant to the filter column CS in batches, centrifuging at 12000 rpm for 2 min, and collecting the filtrate; S17, add 0.3 times the volume of isopropanol to the filtrate, mix by inversion, and transfer to adsorption column CP4; S18, centrifuge at room temperature at 12000 rpm for 1 min, discard the waste liquid in the collection tube, and put the adsorption column back into the collection tube; S19, add 500 µL of deproteinized solution PD to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, pour out the waste liquid in the collection tube, and place the adsorption column CP4 in the collection tube; S110, add 600 µL of rinsing solution PW to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, pour out the waste liquid in the collection tube, and place the adsorption column CP4 in the collection tube; S111, add 600 µL of rinse solution PW to the adsorption column CP4, centrifuge at 12000 rpm for 1 min, and discard the waste liquid in the collection tube; S112, placing the adsorption column CP4 back into the collection tube, centrifuging at 12000 rpm for 2 min, and leaving it at room temperature for several minutes to dry the remaining rinse solution in the adsorption material; S113, place the adsorption column CP4 in a clean centrifuge tube, add 100 µL of elution buffer TB to the middle part of the adsorption membrane, place at room temperature for 2 minutes, centrifuge at 12000 rpm for 1 minute to obtain the pLenti-CMV-Ha6-P2A-Hb4-3xFLAG-EF1a-Puro plasmid solution, collect it in a centrifuge tube, and store it at -20°C; S114, use DMEM complete medium supplemented with 10% fetal bovine serum at 37°C and CO 2 Human embryonic kidney cells HEK293T were cultured in an incubator with a concentration of 5% to allow them to grow adherently, with a density of 80% and an epithelial-like vigorous growth state; S115. Before virus packaging, discard the old culture medium, add new DMEM complete medium containing 10% FBS, and continue culturing in the incubator for 5 h; S116. Use 5 µg of pLenti-CMV-Ha6-P2A-Hb4-3xFLAG-EF1a-Puro plasmid solution, 4 µg of lentiviral packaging plasmid psPAX, and 1.5 µg of lentiviral packaging plasmid pMD2.G, add reduced serum medium Opti-MEM to 250 µL to prepare a plasmid mixture; use 31.2 µL of polyetherimide PEI, add reduced serum medium Opti-MEM to 250 µL to prepare polyetherimide transfection reduced serum medium PEI-Opti-MEM; add polyetherimide transfection reduced serum medium PEI-Opti-MEM to the plasmid mixture, flick the tube wall to mix, and incubate at room temperature for 15 minutes; S117, dropwise add the mixed solution of step S116 to the culture solution of step S115, gently shake and mix, and incubate at 37°C and CO 2 Continue to culture in an incubator with a concentration of 5%; S118. After 18 h, the culture medium was aspirated and 5 mL of freshly prepared DMEM complete culture medium containing 10% FBS was added; S119. After 48 h, the culture supernatant was collected, centrifuged, filtered with a 0.45-µm filter membrane, and quickly frozen in liquid nitrogen to obtain the recombinant virus solution, which was stored at -80°C; S120. Take out the frozen CHO-K1 cells from the liquid nitrogen tank, shake them quickly in a 37°C water bath to thaw, transfer the thawed CHO-K1 cells to a centrifuge tube containing 5 mL of DMEM complete medium, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add 4-6 mL of DMEM complete medium and blow evenly, inoculate in a T25 culture flask, and incubate at 37°C and CO. 2 Culture overnight in an incubator with a concentration of 5%. Change the medium the next day and check the cell density. When the cell density reaches 80%-90%, add 1 mL of trypsin for 1 minute to separate the CHO-K1 cells into single cells and terminate the digestion. Centrifuge, discard the supernatant, add DMEM complete medium containing 50% F-12K medium and 10% FBS to resuspend the CHO-K1 cells and count them. S121. Add 500 µL of recombinant virus solution to the six-well plate, and then immediately add 1×10 5 CHO-K1 cells were shaken and cultured in an incubator for 48 h as the experimental group. At the same time, 1×10 5 The CHO-K1 cells were shaken and cultured in an incubator for 48 hours as a control group. S122. After the cells of the experimental group and the control group were cultured for 48 h, the DMEM complete medium containing 8 μg / mL puromycin, F-12K medium and 10% FBS was replaced, and then replaced every 48 h; S123. After 5 days of screening, all CHO-K1 cells in the control group died. At this time, the CHO-K1 cells in the experimental group that were not dead were positive CHO-K1 cells.
3. The method for preparing pangolin scale recombinant keratin-α / β according to claim 1, It is characterized in that The step S2 specifically includes: S21, expanding and culturing the obtained positive CHO-K1 cells with a complete medium containing F-12K and 10% FBS to obtain pangolin scale recombinant keratin-α / β culture fluid; S22. Purify the pangolin scale recombinant keratin-α / β culture medium using a GST-tagged protein purification affinity preloaded column to obtain high-purity pangolin scale recombinant keratin-α / β.
Citation Information
Patent Citations
Recombinant keratin with triple helix structure as well as preparation method and application of recombinant keratin
CN117430687A
Recombinant keratins and production thereof
WO2023200999A1
Cited By
Squama-derived recombinant keratin hydrogel wound dressing and preparation method thereof
CN121534220A
